🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congrats to the 2022 YC Top Companies! This year, we also launched the YC Breakthrough Companies list to highlight the fast-growing companies that have received between $15M-$300M from YC: ycombinator.com/blog/y-combina…

Today is #AMLWorldAwarenessDay! Did you know acute myeloid #leukemia (AML) is a rare aggressive #cancer of the blood 🩸 & bone marrow, and makes up about 1% of cancers? Let’s unite around the world 🌍, increase AML awareness, and support patients with #bloodcancer! #KnowAML

On today, AML World Awareness Day, we'd like to take a second and acknowledge the 60,000+ individuals living, fighting, and coping with their AML diagnosis. You are warriors. You are strong. You are Notable. #AMLWorldAwarenessDay #leukemia #CANCER #PrecisionMedicine

Wow! 4 years running - we've been listed on Y Combinator's top companies, amongst other leaders steering the future of #cancer treatment towards a more personalized one. #lifescienceleaders #predictivemedicine #personalizedmedicine #precisionmedicine

Matching the RIGHT drug to the RIGHT patient is what we're all about. In an interview with our CEO, Thomas Bock highlights his own personal experience with cancer and how here at Notable we are using our platform to match oncology "diamonds in the rough" with the right patients.

See Notable Booth #2454 ASH Dec. 9-12 & sched. meeting. Learn about PPMP & volasertib, potent PLK1 inhibitor proven to induce cell cycle arrest & apoptosis in various cancer cells. notablelabs.com/contact-us by Dec. 11 for exclusive event invite! #ASH23 #AML #MDS

ICYMI: Notable was featured on the front page of the December 10/11, Hematology Daily News distributed at ASH (#ASH23) conference in San Diego. The article, “The Promise of Predictive Medicine is Coming True,” explains how Notable Labs is advancing predictive

Exemplifying the company's strong commitment to research and development of precision treatments for MDS, Notable has donated $60,000 to the MDS Foundation . The donation was formally announced during the MDS Foundation 2023 Satellite Symposium at the 65th ASH

The Notable Predictive Precision Medicines Platform (“PPMP”) has been validated across four clinical studies conducted at global academic cancer research centers.  Through our proprietary PPMP technology, Notable bio-simulates a cancer treatment and aims to predict whether a

Notable announced the advancement of its volasertib Phase 2 program utilizing PPMP to enrich the study population for clinical responders.  Notable is developing its lead drug asset volasertib with its proprietary PPMP for patients with relapsed/refractory acute myelogenous

Notable Predictive Precision Medicine Platform (PPMP) uses AI and machine learning to provide a predictive score for a patient's likelihood to respond to a particular cancer treatment. NOTABLE’s PPMP is designed to identify and select clinically responsive patients prior to

Learn how Notable is pioneering the integration of artificial intelligence (AI) into predictive precision medicine in this informative California Life Sciences (CLS) article, written by Chris Leonardi, Head of Clinical Alliances and Partnerships. Chris explores how predictive precision

Notable will present the following two posters at the American Association for Cancer Research  (AACR ) Annual Meeting, April 5-10, 2024, in San Diego, CA: 1. Guided by a predictive ex vivo test: Bringing the PLK1 inhibitor volasertib back into the clinic for

Check out Notable poster, “Guided by a predictive ex vivo test: Bringing the PLK1 inhibitor volasertib back into the clinic for venetoclax-HMA relapsed/refractory acute myeloid leukemia patients,” presented last week at the AACR 2024 Annual Meeting in San Diego, CA

ICYMI: Notable poster, “Retrospective prediction of clinical response to standard-of-care therapies in acute myeloid leukemia by an ex vivo drug sensitivity assay using cryopreserved primary samples,” presented at the American Association for Cancer Research (AACR ) 2024 in

Our team at Notable  is looking forward to attending the twelfth annual meeting of the Society of Hematologic Oncology (SOHO) (SOHO 2024), September 4-7, 2024, at the George R. Brown Convention Center in Houston, Texas.  We look forward to learning about the latest breakthroughs in the research

Don't miss the Notable poster, “Revival of the Polo-Like Kinase 1 (PLK1) Inhibitor Volasertis In Relapsed/Refractory Acute Myeloid Leukemia,” presented at the twelfth annual meeting of the Society of Hematologic Oncology (SOHO) (SOHO 2024), September 4-7, 2024, at the George R. Brown Convention

Notable team members were energized by the response to our poster at the 12th annual meeting of the Society of Hematologic Oncology (SOHO) (SOHO2024)!  We were privileged to join cutting-edge research companies presenting the latest breakthrough research.  We remain committed to being the leader